Search - tctmd.com

Displaying 81 - 100 of 356

Sort: Relevancy | Date

Presentation JIM 2020

Must Knows About Left Main PCI Outcomes (or Why was EXCEL so Controversial?)

Presenter: Gregg Stone

February 14, 2020

News Daily News

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

Michael O'Riordan

January 17, 2020

News Daily News

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Michael O'Riordan

January 08, 2020

News Daily News

EACTS Calls for Independent Left Main CAD Evidence Review, Urges ESC Input

Shelley Wood

December 20, 2019

Presentation

Response by David Taggart, MD, PhD to the EXCEL Statement

Presenter: David Taggart

December 19, 2019

Taggart Rebuts EXCEL Response, Insisting on Retraction

News Daily News

Taggart Rebuts EXCEL Response, Insisting Concerns Over MI and Mortality Remain

Michael O'Riordan

December 18, 2019

News Features

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

Michael O'Riordan

December 12, 2019

News Daily News

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

Michael O'Riordan

December 10, 2019

News Conference News AHA 2019

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Shelley Wood

November 16, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

News Conference News TCT 2019

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Marcus A. Banks

September 28, 2019

Presentation TCT 2019

Late Benefits From BVS: Theory and Evidence

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

Presenter: Gregg Stone

September 28, 2019

Presentation TCT 2019

Which Patients Are (and Are Not) Candidates for Intravenous Platelet Inhibition During PCI?

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Presenter: Gregg Stone

September 27, 2019

Presentation TCT 2019

Welcome and Introduction

Presenter: Gregg Stone

September 26, 2019

Presentation TCT 2019

Infarct Size Reduction: From the First FDA-Approved Therapy (SSO2) to Novel Approaches

Presenter: Gregg Stone

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

SSO2 Therapy: Clinical Evidence and Outcomes

Presenter: Gregg Stone

September 26, 2019

Advertisement

Must Knows About Left Main PCI Outcomes (or Why was EXCEL so Controversial?)

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

EACTS Calls for Independent Left Main CAD Evidence Review, Urges ESC Input

Response by David Taggart, MD, PhD to the EXCEL Statement

Taggart Rebuts EXCEL Response, Insisting Concerns Over MI and Mortality Remain

EXCEL Investigators Respond to Data Suppression Claims as Debate Erupts Online

EACTS Pulls Out of Left Main Guidelines After BBC Bombshell Alleging EXCEL Trial Cover-up

ISCHEMIA: Invasive Strategy No Better Than Meds for CV Events

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

EXCEL at 5 Years: PCI for Left Main CAD Still Noninferior to CABG

Late Benefits From BVS: Theory and Evidence

EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease

TCT 7: Blinded Outcomes Assessment of Absorb Bioresorbable Scaffolds Implanted With Improved Technique: Two-year Results From the ABSORB IV Randomized Trial

Which Patients Are (and Are Not) Candidates for Intravenous Platelet Inhibition During PCI?

ABSORB 5-Year Pooled Analysis: Improving Very Late Outcomes of the Absorb Bioresorbable Scaffold in Coronary Artery Disease From 4 Randomized Trials

Welcome and Introduction

Infarct Size Reduction: From the First FDA-Approved Therapy (SSO2) to Novel Approaches

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

SSO2 Therapy: Clinical Evidence and Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content